Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez Ruano JJ, Serra MÁ, Gila A, Diago M, Romero-Gómez M, Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, Granados R, Fernández M, Martín AB, Muñoz de Rueda P, Quiles R; Alhambra Spanish Study Group. Salmerón J, et al. Among authors: munoz de rueda p. World J Gastroenterol. 2015 Aug 14;21(30):9163-74. doi: 10.3748/wjg.v21.i30.9163. World J Gastroenterol. 2015. PMID: 26290644 Free PMC article.
Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
Muñoz de Rueda P, Fuentes Rodríguez JM, Quiles Pérez R, Gila Medina A, Martín Álvarez AB, Casado Ruíz J, Ruíz Extremera A, Salmerón J. Muñoz de Rueda P, et al. World J Gastroenterol. 2017 Jul 7;23(25):4538-4547. doi: 10.3748/wjg.v23.i25.4538. World J Gastroenterol. 2017. PMID: 28740342 Free PMC article.
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Romero-Gómez M, et al. Among authors: munoz de rueda p. Gastroenterology. 2005 Mar;128(3):636-41. doi: 10.1053/j.gastro.2004.12.049. Gastroenterology. 2005. PMID: 15765399
[The value of genetics in the era of hepatitis C triple therapy].
Quiles-Pérez R, Pavón-Castillero EJ, Muñoz-de-Rueda P, Carmona I, Salmerón J. Quiles-Pérez R, et al. Among authors: munoz de rueda p. Gastroenterol Hepatol. 2014 Aug-Sep;37(7):427-37. doi: 10.1016/j.gastrohep.2014.04.004. Epub 2014 Jun 16. Gastroenterol Hepatol. 2014. PMID: 24948442 Review. Spanish.
Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial.
Salmerón J, Diago M, Andrade R, Pérez R, Solá R, Romero M, de la Mata M, Granados R, Ruiz-Extremera A, Muñoz de Rueda P. Salmerón J, et al. Among authors: munoz de rueda p, de la mata m. J Viral Hepat. 2007 Feb;14(2):89-95. doi: 10.1111/j.1365-2893.2006.00771.x. J Viral Hepat. 2007. PMID: 17244248 Clinical Trial.
36 results